A Phase I/II, Open-Label Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Allogeneic Mesenchymal Bone Marrow Cells to Subjects for Cutaneous Photoaging

Trial Profile

A Phase I/II, Open-Label Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Allogeneic Mesenchymal Bone Marrow Cells to Subjects for Cutaneous Photoaging

Suspended
Phase of Trial: Phase I/II

Latest Information Update: 20 Oct 2016

At a glance

  • Drugs Ischemia-tolerant mesenchymal stem cells (Primary)
  • Indications Photodamage; Skin aging
  • Focus Adverse reactions
  • Sponsors Stemedica Cell Technologies
  • Most Recent Events

    • 13 Oct 2016 Status changed from recruiting to suspended.
    • 28 Jul 2016 Planned End Date changed from 1 Dec 2017 to 1 Nov 2017.
    • 28 Jul 2016 Planned primary completion date changed from 1 Aug 2017 to 1 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top